CEO Sara Isbell, of Mercaptor was interviewed on CBS Radio and mentions OneHitAway Foundation.
Click Here to Listen Into the Interview.
Mercaptor develops drugs to treat damage, dysfunction, and degeneration of the brain. Their molecules, called captons, are designed to reduce acute and progressive pathologies initiated by neuronal injury. Captons combine three complementary neuroprotective activities into a single small-molecule agent.